Drug Profile

TCT 001

Alternative Names: TCT-001

Latest Information Update: 28 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Tcelltech
Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Glioblastoma

Most Recent Events

04 Aug 2025 E.W.G. and M.P. (founders of TCellTech) have the patent protection for "T CELL RECEPTOR DERIVED BINDING POLYPEPTIDES" in the USA, the European Union, Japan, China and other countries worldwide
04 Aug 2025 Preclinical trials in Glioblastoma in Germany (Parenteral) prior to July 2025 (Tcelltech pipeline, July 2025).
04 Aug 2025 Tcelltech plans a phase I trial for Glioblastoma in 2026 (Tcelltech pipeline, July 2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com